18Aug 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

The study examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. The primary outcome was a composite of worsening heart failure. Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 participants (43.7%) were iron deficient. Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline.

  • #cardiology

Like

Save

Share